{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T08:07:48Z","timestamp":1764835668053,"version":"3.46.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Anesthesia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jclinane.2025.112012","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:48:42Z","timestamp":1759297722000},"page":"112012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of neoadjuvant chemotherapy on the efficacy of sugammadex for neuromuscular block reversal in ovarian cancer patients: A prospective cohort study"],"prefix":"10.1016","volume":"107","author":[{"given":"Xi","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingxi","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinyu","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianbing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jclinane.2025.112012_bb0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.jclinane.2025.112012_bb0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN guidelines\u00ae insights: ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer, version 3.2024","volume":"22","author":"Liu","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.jclinane.2025.112012_bb0020","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3390\/cancers13040626","article-title":"Emerging trends in neoadjuvant chemotherapy for ovarian cancer","volume":"13","author":"Patel","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jclinane.2025.112012_bb0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2020.10.027","article-title":"Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer","volume":"160","author":"Matsuo","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.jclinane.2025.112012_bb0030","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy","volume":"20","author":"Zaj\u0105czkowska","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jclinane.2025.112012_bb0035","first-page":"1569","article-title":"Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance","volume":"26","author":"Guinan","year":"2018","journal-title":"Support Care Cancer"},{"issue":"4\u20136","key":"10.1016\/j.jclinane.2025.112012_bb0040","first-page":"352","article-title":"Targeting mitochondria and oxidative stress in Cancer- and chemotherapy-induced muscle wasting","volume":"38","author":"Huot","year":"2023","journal-title":"Antioxid Redox Signal"},{"issue":"2","key":"10.1016\/j.jclinane.2025.112012_bb0045","doi-asserted-by":"crossref","first-page":"7587","DOI":"10.4081\/ejtm.2018.7587","article-title":"Chemotherapy-induced muscle wasting: an update","volume":"28","author":"Coletti","year":"2018","journal-title":"Eur J Transl Myol"},{"issue":"11","key":"10.1016\/j.jclinane.2025.112012_bb0050","first-page":"1091","article-title":"Effect of neoadjuvant chemotherapy on the rocuronium muscle relaxation in breast cancer patients","volume":"36","author":"Wang","year":"2020","journal-title":"J Clin Anesthesiol"},{"key":"10.1016\/j.jclinane.2025.112012_bb0055","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jclinane.2016.10.025","article-title":"Chemotherapy alters cisatracurium induced neuromuscular blockade characteristics: a prospective cohort study","volume":"36","author":"Zanjani","year":"2017","journal-title":"J Clin Anesth"},{"issue":"4","key":"10.1016\/j.jclinane.2025.112012_bb0060","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4103\/joacp.joacp_104_22","article-title":"Neuromuscular blockade characteristics of cisatracurium in patients receiving chemotherapy: a preliminary study in breast cancer patients","volume":"39","author":"Gupta","year":"2023","journal-title":"J Anaesthesiol Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.jclinane.2025.112012_bb0065","article-title":"Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults","volume":"8","author":"Hristovska","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.jclinane.2025.112012_bb0070","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s12630-023-02527-x","article-title":"Postoperative recurarization after sugammadex administration in two patients who received neoadjuvant chemotherapy: case reports and literature review","volume":"70","author":"Li","year":"2023","journal-title":"Can J Anaesth"},{"issue":"2","key":"10.1016\/j.jclinane.2025.112012_bb0075","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/sja.SJA_721_19","article-title":"Myasthenia gravis and sugammadex: a case report and review of the literature","volume":"14","author":"Dontukurthy","year":"2020","journal-title":"Saudi J Anaesth"},{"issue":"10","key":"10.1016\/j.jclinane.2025.112012_bb0080","first-page":"337","article-title":"Sugammadex is changing the paradigm in neuromuscular blockade in patients with myotonic dystrophy","volume":"29","author":"Teixeira","year":"2019","journal-title":"J Perioper Pract"},{"key":"10.1016\/j.jclinane.2025.112012_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2020.102840","article-title":"Cross-linking of the DNA repair protein O6-alkylguanine DNA alkyltransferase to DNA in the presence of cisplatin","volume":"89","author":"Ming","year":"2020","journal-title":"DNA Repair (Amst)"},{"issue":"19","key":"10.1016\/j.jclinane.2025.112012_bb0090","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: a review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans"},{"issue":"24","key":"10.1016\/j.jclinane.2025.112012_bb0095","doi-asserted-by":"crossref","first-page":"15619","DOI":"10.3390\/ijms232415619","article-title":"Natural Taxanes: from plant composition to human pharmacology and toxicity","volume":"23","author":"Ni\u017enansk\u00fd","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jclinane.2025.112012_bb0100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12885-019-5302-4","article-title":"Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy","volume":"19","author":"Molassiotis","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jclinane.2025.112012_bb0105","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.937856","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN) in patients receiving 4-6 cycles of platinum-based and Taxane-based chemotherapy: a prospective, single-center study from Kosovo","volume":"28","author":"Myftiu","year":"2022","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.jclinane.2025.112012_bb0110","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12984-021-00818-2","article-title":"A review of movement disorders in chemotherapy-induced neurotoxicity","volume":"18","author":"Wang","year":"2021","journal-title":"J Neuroeng Rehabil"},{"issue":"1","key":"10.1016\/j.jclinane.2025.112012_bb0115","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1152\/jn.00260.2020","article-title":"Acute changes in nerve excitability following oxaliplatin treatment in mice","volume":"124","author":"Makker","year":"2020","journal-title":"J Neurophysiol"},{"issue":"5","key":"10.1016\/j.jclinane.2025.112012_bb0120","first-page":"1569","article-title":"Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance","volume":"26","author":"Guinan","year":"2018","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.jclinane.2025.112012_bb0125","doi-asserted-by":"crossref","first-page":"C744","DOI":"10.1152\/ajpcell.00002.2018","article-title":"Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress","volume":"315","author":"Guigni","year":"2018","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"10.1016\/j.jclinane.2025.112012_bb0130","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/biomedicines11030905","article-title":"Chemotherapy-induced molecular changes in skeletal muscle","volume":"11","author":"Pedrosa","year":"2023","journal-title":"Biomedicines"},{"issue":"18","key":"10.1016\/j.jclinane.2025.112012_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e37529","article-title":"Hotspots and trends in satellite cell research in muscle regeneration: a bibliometric visualization and analysis from 2010 to 2023","volume":"10","author":"Huang","year":"2024","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.jclinane.2025.112012_bb0140","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.taap.2014.05.001","article-title":"Mechanisms of cisplatin-induced muscle atrophy","volume":"278","author":"Sakai","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"10.1016\/j.jclinane.2025.112012_bb0145","first-page":"2990","article-title":"Muscle weakness caused by cancer and chemotherapy is associated with loss of motor unit connectivity","volume":"11","author":"Huot","year":"2021","journal-title":"Am J Cancer Res"}],"container-title":["Journal of Clinical Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952818025002739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952818025002739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T08:03:07Z","timestamp":1764835387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952818025002739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":28,"alternative-id":["S0952818025002739"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinane.2025.112012","relation":{},"ISSN":["0952-8180"],"issn-type":[{"type":"print","value":"0952-8180"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of neoadjuvant chemotherapy on the efficacy of sugammadex for neuromuscular block reversal in ovarian cancer patients: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinane.2025.112012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112012"}}